News

174 patients with moderately to severely active Crohn’s disease were enrolled in FITZROY, a double-blind, placebo-controlled Phase 2 study. Patients recruited were either anti-TNF naïve or anti-TNF failures.

Discovered by BioMarin, BMN 250 is being studied in a multicenter, international clinical trial evaluating safety and tolerability, as well as cognitive function of patients with MPS IIIB

Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions. Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for

Fibrocell’s azficel-T has the potential to address the underlying cause of chronic dysphonia by using the patient’s own cells for localized treatment of the scarred vocal cords to

"We have now determined the Phase II dose and monotherapy regimen of L-DOS47 for patients that have limited treatment options in our LDOS002 study," said Mr. Steve Demas,

The study will start in the second quarter of this year at Memorial Sloan Kettering Cancer Center in New York. Clinical costs will be shared by the companies.

The orphan drug status to the drug, Epidiolex, entitles GW Pharmaceuticals to a seven-year exclusive market period. TSC is the third orphan indication that the company is targeting

AbbVie and CytomX will jointly develop and commercialize probody drug conjugates directed against CD71, which is highly expressed several solid and hematologic cancers. Under the deal, CytomX will

The new Center, located on the SBP campus in La Jolla, will bring together experts from SBP and GSK to investigate factors that influence brain function and potentially